Related Experiment Videos
GM1 gangliosidosis type 2 in two siblings
G G Gascon1, P T Ozand, R E Erwin
1Department of Pediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Journal of Child Neurology
|April 1, 1992
Summary
This study identifies GM1 gangliosidosis type 2 in children presenting with developmental arrest and epilepsy. Diagnosis relies on hyperacusis, sea-blue histiocytes, and deficient beta-galactosidase activity, distinguishing it from other rare neurological disorders.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- GM1 gangliosidosis is a rare lysosomal storage disease affecting the central nervous system.
- Type 2 presents in late infancy with progressive neurological decline.
Observation:
- Two siblings exhibited developmental arrest, gait disturbance, dementia, and myoclonic epilepsy starting in their second year.
- Clinical progression included spastic quadriparesis and a decerebrate state.
- Key diagnostic features included hyperacusis, sea-blue histiocytes in bone marrow, and deficient beta-galactosidase activity.
Findings:
- The clinical, pathological, and biochemical profile confirmed GM1 gangliosidosis type 2.
- Beta-galactosidase deficiency was primarily localized to the brain but detectable in peripheral tissues.
- Normal enzyme activities for other lysosomal hydrolases ruled out other storage diseases.
Implications:
- Accurate diagnosis of GM1 gangliosidosis type 2 is crucial for differentiating it from other severe pediatric neurological conditions.
- Understanding the specific enzyme deficiency aids in genetic counseling and potential therapeutic strategies.
- This case highlights the importance of a comprehensive diagnostic approach for rare metabolic encephalopathies.